Biogen Discontinues Controversial Alzheimer's Drug Aduhelm

Company to Redirect Resources Toward Other Drug Candidates After Internal Review

Biogen, a pharmaceutical company, has decided to discontinue the development and marketing of its controversial Alzheimer's drug, Aduhelm.
The decision was made after an internal review of the company's research and development efforts, and not due to any safety or efficacy concerns.
Biogen will now redirect its resources toward developing other drug candidates and advancing Leqembi, another Alzheimer's drug it's marketing with Eisai that won traditional FDA approval last year.
Aduhelm was granted accelerated approval by the FDA in 2021, but its clinical trials showed modest benefits for patients along with potentially dangerous side effects like brain bleeding and swelling.
Biogen will return the rights to Aduhelm to Neurimmune, the Swiss biopharmaceutical company that discovered it.